Michael Wang, Professor in the Department of Lymphoma/Myeloma and the Department of Stem Cell Transplantation and Cellular Therapy at MD Anderson Cancer Center, shared a post on X :

“In Blood Advances, Dolnikova et al of Prague’s Charles University show strong antitumor synergy between the BCL2 inhibitor venetoclax and the BCL-XL inhibitor A1155463 that is preserved even with knockout of BCL2L11. True for MCL, DLBCL, and others.”

Michael Wang

Blockage of BCL-XL overcomes venetoclax resistance across BCL2⁺ lymphoid malignancies irrespective of BIM status published in Blood Advances

Autors: Alexandra Dolnikova, Dmitry Kazantsev, Magdalena Klanova, Eva Pokorna, Dana Sovilj, Cristina Daniela Kelemen, Liliana Tuskova, Eva Hoferkova, Marek Mraz, Karel Helman, Nikola Curik, Katerina Machova Polakova, Ladislav Andera, Marek Trneny, Pavel Klener

Source: Michael Wang/X

Michael Wang: Strong antitumor synergy between venetoclax and A1155463

Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status published in Blood Advances

Blockage of BCL-XL overcomes venetoclax resistance across BCL2⁺ lymphoid malignancies irrespective of BIM status published in Blood Advances